Intravitreal Bevacizumab in Nonarteritic Anterior Ischemic Optic Neuropathy

Intravitreal Bevacizumab in Nonarteritic Anterior Ischemic Optic Neuropathy

Purpose: To evaluate the effect of intravitreal injection of Bevacizumab on improving visual function in patients with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). Methods: In a prospective interventional case series, 11 eyes with vision loss due to (NAION) in less than 15 days of attac...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advances in Bioscience and Clinical Medicine 2014-01, Vol.2 (1), p.23
Hauptverfasser: Heidari, Ebadollah, Niyousha, Mohammad Reza, Heidari, Reza, Rahimi-Aradabili, Babak, Adl, Farzad Hami, Bazzazi, Nooshin
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page 23
container_title Advances in Bioscience and Clinical Medicine
container_volume 2
creator Heidari, Ebadollah
Niyousha, Mohammad Reza
Heidari, Reza
Rahimi-Aradabili, Babak
Adl, Farzad Hami
Bazzazi, Nooshin
description Purpose: To evaluate the effect of intravitreal injection of Bevacizumab on improving visual function in patients with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). Methods: In a prospective interventional case series, 11 eyes with vision loss due to (NAION) in less than 15 days of attack were studied. Visual acuity, perimetry and optic nerve head changes were evaluated 1 week post-intravitreal injection of 1.25mg/0.1 mL Bevacizumab. Results: 5 of patients had improved visual acuity. In all patients optic disc edema resolved either completely or remarkably in 1 week, but there was no significant change in perimetric values. Conclusion: This case series suggest that intravitreal injection of Bevacizumab may be beneficial in treatment of NAION.
doi_str_mv 10.7575/aiac.abcmed.v.2n.1p.18
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1746912544</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3889307521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c754-4b0a2754546e4786fd94450360cb648b5fc6549b3dfbb4eeb127121d59c748de3</originalsourceid><addsrcrecordid>eNpNkMtqwzAQRUVpoaHNLxRD13YleSTZyzT0ERqSTfZCkmWiEMuuZBvSr69NuiizmMPlMgMHoSeCM8EEe1FOmUxp09gqGzPqM9JlpLhBC0pxnhIg-e0_vkfLGE8YY8KKaWCBvja-D2p0fbDqnLzaURn3MzRKJ84nu9ar0NvgemeSlZ-pDckmmqNtpmTfzfnODqHtVH-8PKK7Wp2jXf7tB3R4fzusP9Pt_mOzXm1TIxikoLGiEzDgFkTB66oEYDjn2GgOhWa14QxKnVe11mCtJlQQSipWGgFFZfMH9Hw924X2e7Cxl6d2CH76KIkAXhLKAKYWv7ZMaGMMtpZdcI0KF0mwnNXJWZ28qpOjpF6STpIi_wXeJ2Y-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1746912544</pqid></control><display><type>article</type><title>Intravitreal Bevacizumab in Nonarteritic Anterior Ischemic Optic Neuropathy</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Heidari, Ebadollah ; Niyousha, Mohammad Reza ; Heidari, Reza ; Rahimi-Aradabili, Babak ; Adl, Farzad Hami ; Bazzazi, Nooshin</creator><creatorcontrib>Heidari, Ebadollah ; Niyousha, Mohammad Reza ; Heidari, Reza ; Rahimi-Aradabili, Babak ; Adl, Farzad Hami ; Bazzazi, Nooshin</creatorcontrib><description>Purpose: To evaluate the effect of intravitreal injection of Bevacizumab on improving visual function in patients with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). Methods: In a prospective interventional case series, 11 eyes with vision loss due to (NAION) in less than 15 days of attack were studied. Visual acuity, perimetry and optic nerve head changes were evaluated 1 week post-intravitreal injection of 1.25mg/0.1 mL Bevacizumab. Results: 5 of patients had improved visual acuity. In all patients optic disc edema resolved either completely or remarkably in 1 week, but there was no significant change in perimetric values. Conclusion: This case series suggest that intravitreal injection of Bevacizumab may be beneficial in treatment of NAION.</description><identifier>ISSN: 2203-1413</identifier><identifier>EISSN: 2203-1413</identifier><identifier>DOI: 10.7575/aiac.abcmed.v.2n.1p.18</identifier><language>eng</language><publisher>Footscray: Australian International Academic Centre PTY. Ltd (AIAC)</publisher><ispartof>Advances in Bioscience and Clinical Medicine, 2014-01, Vol.2 (1), p.23</ispartof><rights>Copyright Australian International Academic Centre PTY. Ltd (AIAC) 2014</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Heidari, Ebadollah</creatorcontrib><creatorcontrib>Niyousha, Mohammad Reza</creatorcontrib><creatorcontrib>Heidari, Reza</creatorcontrib><creatorcontrib>Rahimi-Aradabili, Babak</creatorcontrib><creatorcontrib>Adl, Farzad Hami</creatorcontrib><creatorcontrib>Bazzazi, Nooshin</creatorcontrib><title>Intravitreal Bevacizumab in Nonarteritic Anterior Ischemic Optic Neuropathy</title><title>Advances in Bioscience and Clinical Medicine</title><description>Purpose: To evaluate the effect of intravitreal injection of Bevacizumab on improving visual function in patients with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). Methods: In a prospective interventional case series, 11 eyes with vision loss due to (NAION) in less than 15 days of attack were studied. Visual acuity, perimetry and optic nerve head changes were evaluated 1 week post-intravitreal injection of 1.25mg/0.1 mL Bevacizumab. Results: 5 of patients had improved visual acuity. In all patients optic disc edema resolved either completely or remarkably in 1 week, but there was no significant change in perimetric values. Conclusion: This case series suggest that intravitreal injection of Bevacizumab may be beneficial in treatment of NAION.</description><issn>2203-1413</issn><issn>2203-1413</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpNkMtqwzAQRUVpoaHNLxRD13YleSTZyzT0ERqSTfZCkmWiEMuuZBvSr69NuiizmMPlMgMHoSeCM8EEe1FOmUxp09gqGzPqM9JlpLhBC0pxnhIg-e0_vkfLGE8YY8KKaWCBvja-D2p0fbDqnLzaURn3MzRKJ84nu9ar0NvgemeSlZ-pDckmmqNtpmTfzfnODqHtVH-8PKK7Wp2jXf7tB3R4fzusP9Pt_mOzXm1TIxikoLGiEzDgFkTB66oEYDjn2GgOhWa14QxKnVe11mCtJlQQSipWGgFFZfMH9Hw924X2e7Cxl6d2CH76KIkAXhLKAKYWv7ZMaGMMtpZdcI0KF0mwnNXJWZ28qpOjpF6STpIi_wXeJ2Y-</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Heidari, Ebadollah</creator><creator>Niyousha, Mohammad Reza</creator><creator>Heidari, Reza</creator><creator>Rahimi-Aradabili, Babak</creator><creator>Adl, Farzad Hami</creator><creator>Bazzazi, Nooshin</creator><general>Australian International Academic Centre PTY. Ltd (AIAC)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AYAGU</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20140101</creationdate><title>Intravitreal Bevacizumab in Nonarteritic Anterior Ischemic Optic Neuropathy</title><author>Heidari, Ebadollah ; Niyousha, Mohammad Reza ; Heidari, Reza ; Rahimi-Aradabili, Babak ; Adl, Farzad Hami ; Bazzazi, Nooshin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c754-4b0a2754546e4786fd94450360cb648b5fc6549b3dfbb4eeb127121d59c748de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Heidari, Ebadollah</creatorcontrib><creatorcontrib>Niyousha, Mohammad Reza</creatorcontrib><creatorcontrib>Heidari, Reza</creatorcontrib><creatorcontrib>Rahimi-Aradabili, Babak</creatorcontrib><creatorcontrib>Adl, Farzad Hami</creatorcontrib><creatorcontrib>Bazzazi, Nooshin</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Australia &amp; New Zealand Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Advances in Bioscience and Clinical Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Heidari, Ebadollah</au><au>Niyousha, Mohammad Reza</au><au>Heidari, Reza</au><au>Rahimi-Aradabili, Babak</au><au>Adl, Farzad Hami</au><au>Bazzazi, Nooshin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravitreal Bevacizumab in Nonarteritic Anterior Ischemic Optic Neuropathy</atitle><jtitle>Advances in Bioscience and Clinical Medicine</jtitle><date>2014-01-01</date><risdate>2014</risdate><volume>2</volume><issue>1</issue><spage>23</spage><pages>23-</pages><issn>2203-1413</issn><eissn>2203-1413</eissn><abstract>Purpose: To evaluate the effect of intravitreal injection of Bevacizumab on improving visual function in patients with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). Methods: In a prospective interventional case series, 11 eyes with vision loss due to (NAION) in less than 15 days of attack were studied. Visual acuity, perimetry and optic nerve head changes were evaluated 1 week post-intravitreal injection of 1.25mg/0.1 mL Bevacizumab. Results: 5 of patients had improved visual acuity. In all patients optic disc edema resolved either completely or remarkably in 1 week, but there was no significant change in perimetric values. Conclusion: This case series suggest that intravitreal injection of Bevacizumab may be beneficial in treatment of NAION.</abstract><cop>Footscray</cop><pub>Australian International Academic Centre PTY. Ltd (AIAC)</pub><doi>10.7575/aiac.abcmed.v.2n.1p.18</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2203-1413
ispartof Advances in Bioscience and Clinical Medicine, 2014-01, Vol.2 (1), p.23
issn 2203-1413
2203-1413
language eng
recordid cdi_proquest_journals_1746912544
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
title Intravitreal Bevacizumab in Nonarteritic Anterior Ischemic Optic Neuropathy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T04%3A42%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravitreal%20Bevacizumab%20in%20Nonarteritic%20Anterior%20Ischemic%20Optic%20Neuropathy&rft.jtitle=Advances%20in%20Bioscience%20and%20Clinical%20Medicine&rft.au=Heidari,%20Ebadollah&rft.date=2014-01-01&rft.volume=2&rft.issue=1&rft.spage=23&rft.pages=23-&rft.issn=2203-1413&rft.eissn=2203-1413&rft_id=info:doi/10.7575/aiac.abcmed.v.2n.1p.18&rft_dat=%3Cproquest_cross%3E3889307521%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1746912544&rft_id=info:pmid/&rfr_iscdi=true